HORMAD1 and cancer: (2015), who first demonstrated a recombination‐associated function for HORMAD1 in cancer cells, have postulated that aberrant expression of HORMAD1 disrupts the normal homologous recombination repair pathway driven by the recombinase RAD51 resulting in a preference for a distinct DSB repair pathway, one that makes triple‐negative breast cancer cells expressing HORMAD1 more responsive to platinum‐based chemotherapy.